Poniard Pharmaceuticals (PARD) Stock Chart & Stock Price History Add Compare Share Share Chart Stock AnalysisChartBuy This Stock Poniard Pharmaceuticals Stock Price Performance The Poniard Pharmaceuticals (PARD) stock chart highlights key performance trends across multiple timeframes.Five years ago, the stock traded at $0.07, representing a 100.00% decrease over that period. At the time, it had a market cap of and a volume of 0 shares. Receive PARD Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Poniard Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address 3 Month PerformanceN/A5 Year PerformanceN/A PARD Stock Chart for Monday, August, 25, 2025 PARD Chart by TradingView Poniard Pharmaceuticals Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel No price data in the selected date range. Related Companies 180 Life Sciences Stock Price Chart 4D pharma Stock Price Chart 4Front Ventures Stock Price Chart Abattis Bioceuticals Stock Price Chart Abcam Stock Price Chart Acusphere Stock Price Chart Aeolus Pharmaceuticals Stock Price Chart Aesther Healthcare Acquisition Stock Price Chart Agentix Stock Price Chart Ainos Stock Price Chart Receive PARD Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Poniard Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (OTCMKTS:PARD) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Poniard Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Poniard Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access